Key Takeaway: Dr. Jonathan Javitt, CEO of NRx Pharmaceuticals, and Anne Dunsmore, Founder of Angel Force USA, are collaborating to combat veteran suicide. Their initiative emphasizes the use of advanced neuroplastic therapies and aims to raise awareness across the nation. This partnership seeks to provide effective solutions and support for veterans in need.
Price reaction · baseline $2.14 (2025-11-21T18:26:00.000Z) · hit during market hours · clean, no other NRXP news in the window
day 0 close · peak
-0.5%
Market Sentiment Analysis
POSITIVE FACTORS
Joint mission to prevent veteran suicide
Focus on advanced neuroplastic therapies
Nationwide awareness programs to support veterans
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.3%
average across 2 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
NRX-101
Phase 2 · Bipolar Depression
Full Press Release Details
Dr. Jonathan Javitt, CEO of NRx Pharmaceuticals, and Anne Dunsmore, Founder of Angel Force USA, discuss their joint mission to prevent veteran suicide through advanced neuroplastic therapies and nationwide awareness programs
Frequently Asked Questions
What is the mission of NRx and Angel Force USA?
Their mission is to prevent veteran suicide through advanced neuroplastic therapies.
Who are the key figures in this initiative?
Dr. Jonathan Javitt is the CEO of NRx Pharmaceuticals, and Anne Dunsmore is the Founder of Angel Force USA.
What therapies are being used to combat veteran suicide?
They focus on advanced neuroplastic therapies as part of their approach.
How do they plan to raise awareness?
They aim to implement nationwide awareness programs to support veterans.